Hard To Treat Diseases (PINK SHEETS: HTDS): Human Clinical Trial of Embryonic Stem Cell-Based Therapy
10 August 2010 - 11:57PM
Marketwired
Hard to Treat Diseases, Inc. (PINK SHEETS: HTDS) -
The world's first clinical trial of human embryonic stem cell
(hESC) - based therapy for the treatment of acute spinal cord
injuries in man has been approved by FDA and will be performed by
Geron Corporation and the University of California, Irvine. (Source
http://stemcell.uci.edu/).
Professor Mirjana Stojiljkovic, principal scientist and medical
advisor from Slavica BioChem (www.slavicabiochem.com), a subsidiary
of Hard to Treat Diseases, Inc. (PINK SHEETS: HTDS),
http://www.htdsmedical.com said that this is a major breakthrough
for the whole field of regenerative medicine, especially concerning
the treatment of neurodegenerative diseases. As the Geron officials
reported, they are now formally exploring the utility of
hESC-Derived Oligodendrocyte Progenitor Cells (OPC) in other
degenerative CNS disorders including Alzheimer's, multiple
sclerosis (MS) and Canavan disease.
Multiple sclerosis, which is, along with the traumatic brain
injury, in the focus of research of the Slavica BioChem scientific
team, is a demyelinating disease affecting brain and spinal cord.
Demyelination is the process of degeneration of myelin, the
insulating sheath around the nerve fibers. Myelin is produced by
oligodendrocytes. In MS treatment, oligodendrocytes need to be
"replaced" in order to have new myelin produced. This is where the
hESC-Derived Oligodendrocyte Progenitor Cells (OPC) come into play.
Geron team in collaboration with the University of California has
shown in animal models that OPC can improve functional locomotor
behavior after grafting in the injury site seven days after
injury.
Dr Sanja Pekovic, Chief Project Scientist and Chief Strategy
Officer of HTDS adds that the research Slavica Biochem is
performing on MS is along the lines with these general notions in
MS treatment. Namely, Slavica Biochem is performing research on
substances, which can be used as add-on therapy to the hESC-cell
based therapy. These chemicals will be tested for their capability
of promoting stem cell graft survival. Slavica Biochem team also
plans on establishing collaboration on these topics with research
teams from USA, especially after the Agreement on Scientific and
Technological cooperation between the Republic of Serbia and the
United States of America (USA) has been signed in April this year.
See link for further details:
www.nauka.gov.rs/eng/index.php?option=com_content&task=view&id=394&Itemid=55.
In view of the above and further to the company news release of
July 29, 2010 HTDS management continues its diversification of
Slavica Biochem and outright sale discussions with a USA based Bio
Chem company. HTDS management is seeking ways and means to bolster
its share values to its shareholders and generally increase value
to HTDS.
About Mina Mar Group:
Mina Mar Group pioneered the "Go Public Free" program, the first
firm to challenge the short sellers, stock bashers and repeal of
the "Communication Decency Act". Visit www.minamargroup.com/ice to
learn more.
Mina Mar Marketing Group, MMMG (www.minamargroup.net/) offers
publicly traded companies full array of services such as Investor
Relations and maintenance investor awareness.
To be included in company's email database for press releases,
"Friday Tips", industry updates, and company activity that may or
may not be news released, please subscribe for opt-in mailer at
http://www.minamargroup.com/updates.
Safe Harbor Statement
Information in this news release may contain statements about
future expectations, plans, prospects or performance of Hard to
Treat Diseases, Inc. that constitute forward-looking statements for
purposes of the Safe Harbor Provisions under the Private Securities
Litigation Reform Act of 1995. The words or phrases "can be,"
"expects," "may affect," "believed," "estimate," "project" and
similar words and phrases are intended to identify such
forward-looking statements. Hard to Treat Diseases, Inc. cautions
you that any forward-looking information provided by or on behalf
of Hard to Treat Diseases, Inc. is not a guarantee of future
performance. None of the information in this press release
constitutes or is intended as an offer to sell securities or
investment advice of any kind. Hard to Treat Diseases, Inc.'s
actual results may differ materially from those anticipated in such
forward-looking statements as a result of various important
factors, some of which are beyond Hard to Treat Diseases, Inc.'s
control. In addition to those discussed in Hard to Treat Diseases,
Inc.'s press releases, public filings, and statements by Hard to
Treat Diseases, Inc.'s management, including, but not limited to,
Hard to Treat Diseases, Inc.'s estimate of the sufficiency of its
existing capital resources, Hard to Treat Diseases, Inc.'s ability
to raise additional capital to fund future operations, Hard to
Treat Diseases, Inc.'s ability to repay its existing indebtedness,
the uncertainties involved in estimating market opportunities, and
in identifying contracts which match Hard to Treat Diseases, Inc.'s
capability to be awarded contracts. All such forward-looking
statements are current only as of the date on which such statements
were made. Hard to Treat Diseases, Inc. does not undertake any
obligation to publicly update any forward-looking statement to
reflect events or circumstances after the date on which any such
statement is made or to reflect the occurrence of unanticipated
events.
Contacts: Investor Relations: 1-647-426-1640,
www.minamargroup.net/helpdesk Investor Relations Department
Inquiry, www.minamargroup.net (IR), for (M&A) and Corporate
Matters, www.minamargroup.com Hard to Treat Diseases, Inc:
corporate@htdsmedical.com
Hard To Treat Diseases (CE) (USOTC:HTDS)
Historical Stock Chart
From Dec 2024 to Jan 2025
Hard To Treat Diseases (CE) (USOTC:HTDS)
Historical Stock Chart
From Jan 2024 to Jan 2025
